Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ11340MR)

This product GTTS-WQ11340MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Humanized
RefSeq	NM_001178098.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	930
UniProt ID	P15391

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11340MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ4719MR	IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	BOS161721
GTTS-WQ7376MR	IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	FZD8-Fc
GTTS-WQ8780MR	IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	IBI-306
GTTS-WQ13919MR	IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	REGN2477
GTTS-WQ434MR	IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	3C23K
GTTS-WQ6926MR	IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	ENIA11
GTTS-WQ8084MR	IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	h5G1.1HuG2/G4
GTTS-WQ7312MR	IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	FPA-144

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST